-
1
-
-
33847323129
-
Epidermal growth factor receptor mutations in lung cancer
-
S.V. Sharma, D.W. Bell, and J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat. Rev. Cancer 7 2007 169 181
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 169-181
-
-
Sharma, S.V.1
Bell, D.W.2
Settleman, J.3
-
2
-
-
35548962203
-
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
-
T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci. 98 2007 1817 1824
-
(2007)
Cancer Sci.
, vol.98
, pp. 1817-1824
-
-
Mitsudomi, T.1
Yatabe, Y.2
-
3
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
-
(2004)
N. Engl. J. Med.
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
-
4
-
-
4444344330
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
-
W. Pao, V. Miller, and M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc. Natl. Acad. Sci. U.S.A. 101 2004 13306 13311
-
(2004)
Proc. Natl. Acad. Sci. U.S.A.
, vol.101
, pp. 13306-13311
-
-
Pao, W.1
Miller, V.2
Zakowski, M.3
-
5
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
T.S. Mok, Y.L. Wu, and S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N. Engl. J. Med. 361 2009 947 957
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
-
6
-
-
77953930730
-
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
-
M. Maemondo, A. Inoue, and K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N. Engl. J. Med. 362 2010 2380 2388
-
(2010)
N. Engl. J. Med.
, vol.362
, pp. 2380-2388
-
-
Maemondo, M.1
Inoue, A.2
Kobayashi, K.3
-
7
-
-
35648949422
-
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations
-
discussion 1680
-
D.B. Costa, B. Halmos, and A. Kumar BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations PLoS Med. 4 2007 1669 1679 discussion 1680
-
(2007)
PLoS Med.
, vol.4
, pp. 1669-1679
-
-
Costa, D.B.1
Halmos, B.2
Kumar, A.3
-
8
-
-
84875721996
-
BIM, PUMA, and the achilles' heel of oncogene addiction
-
A. Roulston, W.J. Muller, and G.C. Shore BIM, PUMA, and the achilles' heel of oncogene addiction Sci. Signal. 6 2013 pe12
-
(2013)
Sci. Signal.
, vol.6
, pp. 12
-
-
Roulston, A.1
Muller, W.J.2
Shore, G.C.3
-
9
-
-
13844317894
-
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
-
S. Kobayashi, T.J. Boggon, and T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792
-
(2005)
N. Engl. J. Med.
, vol.352
, pp. 786-792
-
-
Kobayashi, S.1
Boggon, T.J.2
Dayaram, T.3
-
10
-
-
18244371651
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
-
W. Pao, V.A. Miller, and K.A. Politi Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med. 2 2005 e73
-
(2005)
PLoS Med.
, vol.2
, pp. 73
-
-
Pao, W.1
Miller, V.A.2
Politi, K.A.3
-
11
-
-
49149118719
-
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
-
D. Li, L. Ambrogio, and T. Shimamura BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 27 2008 4702 4711
-
(2008)
Oncogene
, vol.27
, pp. 4702-4711
-
-
Li, D.1
Ambrogio, L.2
Shimamura, T.3
-
12
-
-
84862785051
-
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial
-
V.A. Miller, V. Hirsh, and J. Cadranel Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial Lancet Oncol. 13 2012 528 538
-
(2012)
Lancet Oncol.
, vol.13
, pp. 528-538
-
-
Miller, V.A.1
Hirsh, V.2
Cadranel, J.3
-
13
-
-
84862819699
-
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
-
J.C. Yang, J.Y. Shih, and W.C. Su Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial Lancet Oncol. 13 2012 539 548
-
(2012)
Lancet Oncol.
, vol.13
, pp. 539-548
-
-
Yang, J.C.1
Shih, J.Y.2
Su, W.C.3
-
14
-
-
16244400108
-
Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody
-
J. Harding, and B. Burtness Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody Drugs Today (Barc.) 41 2005 107 127
-
(2005)
Drugs Today (Barc.)
, vol.41
, pp. 107-127
-
-
Harding, J.1
Burtness, B.2
-
15
-
-
84890862301
-
EGF receptor trafficking: Consequences for signaling and cancer
-
A. Tomas, C.E. Futter, and E.R. Eden EGF receptor trafficking: consequences for signaling and cancer Trends Cell Biol. 24 2014 26 34
-
(2014)
Trends Cell Biol.
, vol.24
, pp. 26-34
-
-
Tomas, A.1
Futter, C.E.2
Eden, E.R.3
-
16
-
-
63649086486
-
The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins
-
C. Raiborg, and H. Stenmark The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins Nature 458 2009 445 452
-
(2009)
Nature
, vol.458
, pp. 445-452
-
-
Raiborg, C.1
Stenmark, H.2
-
17
-
-
84906911022
-
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
-
Y.Y. Janjigian, E.F. Smit, and H.J. Groen Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Cancer Discov. 4 2014 1036 1045
-
(2014)
Cancer Discov.
, vol.4
, pp. 1036-1045
-
-
Janjigian, Y.Y.1
Smit, E.F.2
Groen, H.J.3
-
18
-
-
70349684791
-
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
-
L. Regales, Y. Gong, and R. Shen Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer J. Clin. Invest. 119 2009 3000 3010
-
(2009)
J. Clin. Invest.
, vol.119
, pp. 3000-3010
-
-
Regales, L.1
Gong, Y.2
Shen, R.3
-
20
-
-
10444267243
-
Cetuximab (Erbitux) - An emerging targeted therapy for epidermal growth factor receptor-expressing tumours
-
M. Ng, and D. Cunningham Cetuximab (Erbitux) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours Int. J. Clin. Pract. 58 2004 970 976
-
(2004)
Int. J. Clin. Pract.
, vol.58
, pp. 970-976
-
-
Ng, M.1
Cunningham, D.2
-
21
-
-
35648953299
-
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics
-
discussion 1690
-
M.S. Cragg, J. Kuroda, and H. Puthalakath Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics PLoS Med. 4 2007 1681 1689 discussion 1690
-
(2007)
PLoS Med.
, vol.4
, pp. 1681-1689
-
-
Cragg, M.S.1
Kuroda, J.2
Puthalakath, H.3
-
22
-
-
33644865025
-
Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function
-
X.J. Qi, G.M. Wildey, and P.H. Howe Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function J. Biol. Chem. 281 2006 813 823
-
(2006)
J. Biol. Chem.
, vol.281
, pp. 813-823
-
-
Qi, X.J.1
Wildey, G.M.2
Howe, P.H.3
-
23
-
-
75749096347
-
The endocytic matrix
-
G. Scita, and P.P. Di Fiore The endocytic matrix Nature 463 2010 464 473
-
(2010)
Nature
, vol.463
, pp. 464-473
-
-
Scita, G.1
Di Fiore, P.P.2
-
24
-
-
71949085528
-
Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src
-
B.M. Chung, S.M. Raja, and R.J. Clubb Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src BMC Cell Biol. 10 2009 84
-
(2009)
BMC Cell Biol.
, vol.10
, pp. 84
-
-
Chung, B.M.1
Raja, S.M.2
Clubb, R.J.3
|